CRISPR Therapeutics (CRSP)
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
New Form 8-K - CVRx, Inc. Filed: 2025-08-04 AccNo: 0001104659-25-073638 Size: 294 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
New Form 8-K - agilon health, inc. Filed: 2025-08-04 AccNo: 0001628280-25-037426 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or …
New Form 8-K - SI-BONE, Inc. Filed: 2025-08-04 AccNo: 0001459839-25-000073 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
agilon health - agilon health Reports Second Quarter 2025 Results
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
agilon health - agilon health Announces Leadership Transition
agilon health Announces Leadership Transition
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance
Ardelyx Announces Changes to the Executive Leadership Team